Fig. 2From: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive declineRead-out frequencies of the Aβ structure biomarker from the baseline plasma of 203 SCD subjects. Out of 180 non-converted SCD subjects, 51 were classified as having normal secondary structure distribution similar to that in the non-diseased subjects. They are above 1646 cm− 1 (green). Seventy-seven subjects showed low misfolding (i.e., ≤ 1646 cm− 1 and ≥ 1644 cm− 1) (yellow) and 52 had a high Aβ misfolding status (below 1644 cm− 1) (red). Out of 22 converters showing misfolding, 16 showed high misfolding and six converters showed low misfolding. The misfolding as a structure biomarker correctly predicted all 22 converters within the 6 years of follow-up. In subjects with normal misfolding, one converter was observed. This individual acquired the disease after 9.15 years. In addition, for each patient, the CSF status is displayed (● = normal; ▲ = abnormal), and the length of follow-up time is colored ascending from light gray to black ( = [≤ 2.5], = [> 2.5–< 6.0], = [≥ 6.0–< 9.0], ● = [≥ 9.0])Back to article page